Even among breast cancer patients without metastasis to axillary lymph nodes, early recurrence can occur. To determine the risk factors for early recurrence, we performed a case-control study between 32 patients with an early recurrence of breast cancer and 122 patients without recurrence, in which tumor size, age of patient and date of operation were matched. In all 154 node-negative patients, followed up over a 13.1-year median period, expression of p53, c-erbB-2 and cathepsin D in the primary tumor were studied immunohistochemically in paraffin-embedded tissues and were compared with morphologic factors such as histologic grade and invasive growth. Univariate analysis showed that nuclear p53 immunoreaction was significantly predictive of early recurrence [risk ratio (RR) 3.3]. Likewise, cathepsin D (RR 0.22) was significantly negatively associated; however, when the risk ratio was analyzed in terms of intensity of cathepsin D staining, no superior survival was found for patients with strongly positive tumors. Overexpression of c-erbB-2 protein was not associated with outcome by either univariate or multivariate analysis. As a whole, histologic grade was confirmed as being a strong predictor (RR 42.6) and multivariate analysis showed that only histologic grade was a significant risk factor for early recurrence. p53 immunoreaction was not a significant independent factor because it was closely linked to histologic grade (P = 0.002), especially to a high mitotic index (P < 0.001). Moreover, in 14 patients with 'special histologic types' of invasive carcinomas and no recurrence, all were p53-negative except one medullary carcinoma. Nuclear p53 immunoreaction is useful in supporting histologic grade to detect a high-risk for early recurrence in node-negative patients who may be eligible for systemic adjuvant therapy.
INTRODUCTION
Among Western females, about 25% of patients with primary breast cancer without lymph node metastasis develop and die from tumor recurrence (1, 2) In Japan the ratio is around 10%, reflecting the fact that the natural history of breast cancer differs between patients in the Western countries and those in Japan (3, 4) . Recent prospective, randomized clinical trials in patients with node-negative breast cancer have found small but significant improvements in both disease-free and overall survival resulting from the use of adjuvant chemotherapy (5, 6) . In order to tailor therapy to appropriate patients on the basis of the biological characteristics of the individual tumor, to avoid excessive treatment and to decrease treatment costs for these patients, the development of new and more powerful prognostic indicators that correlate with clinical outcome would help in the selection of patients for whom systemic adjuvant chemotherapy is necessary.
Recently, p53 protein detected by immunohistochemical methods has been reported to be an independent prognostic factor and a new predictor of node-negative patients at high risk of recurrence and death (7) (8) (9) (10) . The p53 tumor suppressor gene codes for a nuclear phosphoprotein thought to regulate the proliferation of normal cells. Mutations in the p53 gene, one of the most common genetic defects in human cancer, have been shown to result in a conformational change in and prolongation of the half-life of the p53 protein. It also causes accumulation of the p53 protein in tumor cell nuclei, which appears to be involved in the development and progression of many neoplastic diseases including human breast cancer (11) (12) (13) .
We are interested in evaluating p53 immunoreaction as a relative risk factor for node-negative breast cancer and comparing it with new biologic markers such as c-erbB-2 and cathepsin D as well as conventional morphologic factors. Among many prognostic factors, the size of the primary tumor is currently the best established and most reliable in node-negative patients (14) . We identified 32 patients with a primary breast cancer v5 cm in size that had recurred within 2 years. In this study the features of patients with an early recurrence were demonstrated by careful comparison with patients without recurrence in order to elucidate the risk factors for early recurrence.
MATERIALS AND METHODS

PATIENTS
Our records showed that 5211 primary breast cancer patients had received standard radical or modified radical mastectomies at the National Cancer Center Hospital between 1962 and 1991. From these patients, we selected 154 in whom metastases were not detected microscopically in the axillary lymph nodes and tumor size was v5 cm in diameter on palpation. Thirty-two patients (1.4% of 2230 patients with early stage breast cancer) suffered recurrence within 2 years after surgery, and for each of these, three or four control cases were selected. These 32 patients were all Japanese women aged between 26 and 71 years (median age 46.2 years). Tumor size ranged from 3 mm to 50 mm (median size: 22.6 mm).
In the control patients, primary tumor size (v2.0 cm, or 2.1-5.0 cm ), absence of axillary lymph-node metastasis, the date of the operation (±5 years) and the age at operation (±5 years) were matched to those of the early-recurrence patients. None of the control patients developed a recurrence of breast cancer within 5 years after surgery. The mean follow-up period for the controls was 13.1 years.
Twenty-six of the 32 patients (81.3%) died due to cancer between 10 months and 14 years after mastectomy (median survival period: 3 years 8 months). The other six living patients were recent cases, except one who had had chest wall excision for a local recurrence in 1970. This indicates that early recurrence in node-negative patients is a strong predictor of death from the tumor.
Twelve of the 32 patients (37.5%) developed a local recurrence; of these 10 had died from their tumor. In the remaining 20 patients (62.5%), who had distant metastases, the site of the first recurrence was the lung or pleura in 10, bone in four, and liver in three.
Histologic grading of the primary tumor was performed according to a system based on a modification of the WHO classification (15) . Briefly, the modified histologic grade of the primary lesion was a summed score comprising (a) the degree of structural atypia, (b) the degree of nuclear atypia and (c) the number of mitotic figures. Individual cases were categorized as grade 1 when the sum of scores was 3 or 4; as grade 2 when the sum was 5, 6 or 7; and as grade 3 when the sum was 8 or 9. The number of mitotic figures was counted per 10 high-power fields (×400).
IMMUNOHISTOCHEMISTRY
Formalin-fixed paraffin-embedded tissue blocks containing the breast carcinoma lesions were sliced into 3 µm-thick sections.
The sections were deparaffinized in xylene, and rehydrated in a descending series of ethanol concentrations, ending in phosphate buffered saline (PBS). As an antigen retrieval procedure, the sections were placed in a hot water bath set at 90_C for 15 min and left to cool for 15 min. They were incubated for 30 min in 0.3% hydrogen peroxide in methanol and then incubated for 10 min in 2% normal swine serum in PBS in order to abolish any endogenous peroxidase activity and to diminish any non-specific antibody binding. The sections were incubated at 4_C overnight with anti-p53 antibody RSP53 at a dilution of 1:10 000. RSP53 was a rabbit polyclonal antibody against a synthetic peptide corresponding to amino acid residues 54-69 (C-F-T-E-D-P-G-P-D-E-A-P-R-M-P-E-A) (Nichirei Inc., Tokyo) of p53. After thorough washing with PBS, the sections were incubated for 30 min with 1:200 diluted biotinylated horse anti-rabbit immunoglobulin as a secondary antibody (Vector Laboratories Inc., Burlingame, CA) then for an additional 30 min with 1:100 diluted avidin-biotinylperoxidase complex (Vectastain, Vector, Burlingame, CA). The peroxidase reaction was performed using 0.02% 3,3′-diaminobenzidine tetrahydrochloride-hydrogen peroxidase as a chromogen, with 0.01 M sodium azide as an endogenous peroxidase inhibitor, in Tris buffer (pH 7.6) for 5 to 10 min. Nuclear counterstaining was performed with 2% methyl green (Chroma, Kongen, Germany). Before each step, the sections were washed three times (for 5 min each time) with PBS.
Commercially available polyclonal antibodies against c-erbB-2 protein (Nichirei Inc., Tokyo) and cathepsin D (Novocastra Laboratories Ltd, Newcastle, UK) were used for immunohistochemistry at dilutions of 1:200 and 1:600 respectively. Immunohistochemical staining was carried out according to the method described above but without the antigen retrieval procedure.
When the surface of the cell membrane was distinctly stained for c-erbB-2, the intensity of staining was categorized as strongly positive (16) . The weakly positive group showed faint staining in which the difference between membrane and cytoplasm was often unclear. The intensity of staining for cathepsin D was categorized as follows: strongly positive when positive staining for cathepsin D occurred in greater than 10% of cancer cells; weakly positive when 1% to 10% of the cells were positive for cathepsin D.
STATISTICAL ANALYSIS
The χ 2 test was used to compare nuclear p53 immunoreaction and other clinicopathologic factors (histologic type, histologic grade, and immunohistochemical staining for c-erbB-2 protein and cathepsin D ). Conditional logistic regression analysis was used to calculate the risk factor against recurrence and 95% confidence intervals (CI) for each prognostic factor (17) . All calculations were performed using the SAS statistical software package (SAS Institute Inc., Cary, NC).
RESULTS
The cancer patients were classified into two groups according to the percentages of nuclei distinctly stained with the anti-p53 antibody; a p53-positive group in which w10 % of the nuclei were stained for p53 , and a p53-negative group in which <10 % of the nuclei exhibited p53 accumulation (Fig. 1 ). The negative group included patients with only one or two cancer cells stained faintly in the nuclei.
Out of the 154 breast cancer patients included in the study, 33 (21.4%) were judged to be p53-positive. Non-cancerous cells were consistently negative in all patients. p53-positive cancer was found in 13 of the 32 patients (40.6%) who developed recurrence within 2 years. These 13 are 39.4% of the 33 patients positive for p53. However, only 19 (15.6%) of the 122 patients without recurrence were p53-positive. The incidence of p53 immunoreaction was significantly higher in the early-recurrence group than in the norecurrence one (P = 0.003). Univariate conditional logistic regression analysis showed that the risk ratio for early recurrence was 3.28 times higher if the breast cancer was p53-positive (Table 1) .
Among the patients in each histologic grade, p53 was associated with early recurrence only in grade 2 : among the 12 patients with recurrence in grade 2, six (50%) were judged to be p53-positive. On the other hand, among 75 controls in grade 2, p53 was positive in only 10 (13%). The relationship between histologic grade and p53 immunoreaction is shown in Table 2 .
Cathepsin D immunostaining was seen as coarse or tiny granules diffusely distributed in the cytoplasm of the breast cancer cells. Stromal macrophages were also stained positively, but these cells could easily be distinguished from cancer cells by their morphology. In 92 (60%) of the 154 patients cathepsin D was stained in the cancer cells. The intensity of tumor staining (examples in Fig. 2) was variable: as shown in Table 1, 22 showed strongly positive staining, while 70 showed weakly positive staining, (in which cathepsin D-positive cancer cells comprised fewer than 10% of the total number of tumor cells).
When tumors were graded as strongly positive (22/154, 14.3%), weakly positive (70/154, 45.5%), or negative (62/154, 40.3%), cathepsin D immunoreactivity on this three point scale was associated with a significant prognostic advantage (P = 0.007). However, the risk ratio for early recurrence was rather lower in the weakly positive group than in the strongly positive one (negative versus weakly positive, 0.22, negative versus strongly positive, 0.45) ( Table 1 ). Immunostaining for c-erbB-2 is shown in Fig 3. As reported previously (16) , the intensity of c-erbB-2 staining was strongly associated with the copy number of the c-erbB-2 gene. Nineteen (12.3%) of 154 cases were graded as strongly positive and 15 (9.7%) as weakly positive. The remaining 120 (78%) tumors stained negative. In this study using node-negative cases, there was no significant difference in the incidence of strong c-erbB-2 staining between the early recurrence group and controls (Table 1) .
Histologic grade correlated significantly with early recurrence. Univariate analysis showed that patients with grade 3 tumors had a risk of early recurrence 43 times higher than those with grade 1 tumors, while those in grade 2 still had a risk five times higher. In 26 patients who had grade 1 tumors, 25 (96%) were alive without recurrent disease.
Histologic classification was also significantly related to early recurrence. Invasive carcinomas were 2.29 times more likely to lead to early recurrence than noninvasive carcinomas. Of the patients with invasive carcinoma, all 14 with special types other than invasive ductal and invasive lobular carcinomas remained free from recurrence. The number of patients with special types and their p53 immunostaining status are listed in Table 3 . When the patients were classified into three histologic grade groups, 39% (16/41) of grade 3 carcinomas were p53-positive compared with 18% (16/87) of grade 2 and 4% (1/26) of grade 1 tumors (Table 2) . Thus p53-positive cancer was strongly associated with high histologic grade (P = 0.002). Among the three elements of the histologic grading, p53 was closely associated with high numbers of mitotic figures (P < 0.001). Although there was no significant correlation between p53 and histologic types (P = 0.257), in the 14 patients with special-type carcinomas, which were considered to be low grade invasive carcinomas, p53 was negative except in one patient with medullary carcinoma (Table 3 ). These results suggest that p53-positivity was closely linked to the morphologic aggressiveness of the tumor. There was no significant correlation between p53-positive cancer and cathepsin D staining or invasive growth. However, 42.1% (8/19) of p53-positive cancers showed strong staining for c-erbB-2 protein (P = 0.063). There was no correlation between the incidence of cathepsin D positivity and histologic grade, invasive growth, or c-erbB-2 protein immunoreactivity.
Multivariate conditional logistic regression analysis showed that only histologic grade was a significant variable for predicting early recurrence in node-negative patients. The prognostic significance of p53, which was observed in univariate analysis, was absorbed in the influence of the prognostic value of histologic grade.
DISCUSSION
We have performed a case-control study between early-recurrent and non-recurrent node-negative breast cancer groups closely matched for tumor size, age of patient and date of operation. The results revealed significant differences in the incidence of p53 immunoreaction and the distribution of histologic grades between the early-recurrent and non-recurrent groups.
In our previous study on a smaller number of breast cancer patients, nuclear p53 immunoreaction correlated with a shorter overall survival time (7) . Other immunohistochemical studies of p53 in a number of patients reported a significant correlation between nuclear accumulation of p53 protein and adverse prognosis (17-21). Thor et al. first demonstrated p53 immunoreaction to be a new independent marker for a poorer prognosis in breast cancer using retrospective data for 304 patients (8). Allred et al. indicated that nuclear p53 immunoreaction was a risk factor for early recurrence in 700 node-negative breast cancer patients (10). Using conditional logistic regression analysis, the risk of early recurrence in p53 immunoreaction-positive cases was estimated to be 3.28 times as high as that in p53-negative cases. This result confirmed that p53 immunoreaction in cancer cell nuclei can be a helpful tool in identifing node-metastasis negative breast cancer groups with a high risk of early recurrence. Several histologic grading systems have been described and shown to have prognostic value in the evaluation of breast carcinoma (22) (23) (24) . All of these systems take into account the architectural arrangement of cells, the degree of nuclear atypia, and the mitotic rate. Although the acceptance of histologic grade in prognostic evaluation has sometimes been impeded by the problem of interobserver reproducibility (25) (26) (27) , the practical significance of histologic grade as a prognostic indicator in node-negative breast cancer appears to have been established in this study.
p53 immunoreaction would help to prove objectively the validity of a histologic grading system because p53 was strongly correlated with grade in our study. Patients with grade 1 carcinoma have previously been considered not to require adjuvant chemotherapy (14) . Among our 26 grade 1 carcinomas, 25 were p53-negative, and this would strongly support their low grade clinical malignancy. Conversely, in grade 3 patients adjuvant therapy seems clearly indicated. However, in grade 2 carcinomas, which rely on judgment as they constitute an intermediate category, the decision appears difficult. Our result showing that p53 was correlated with early recurrence in grade 2 carcinomas may help in planning postoperative therapy for such patients.
Regarding the immunohistochemical method of detecting p53 protein, the antigen retrieval method has been shown effective in performing p53 staining reproducibly (28, 29) . During the simplified antigen retrieval procedure used in the present study, different technicians performed the p53 immunostaining three times, and the results were completely reproducible. Thus, in immunohistochemical studies to examine p53 protein retrospectively in archival materials, the antigen retrieval procedure was confirmed as being very effective.
c-erbB-2 staining was not associated with early recurrence in this study. This was probably because c-erbB-2 was frequently stained in the intraductal component in the non-recurrent group. The proportion of intraductal component in the breast cancer tissue diminished in parallel with advancing clinical stage. The association of c-erbB-2 staining or gene amplification with poor prognosis in breast cancer has also been reported to be much stronger for patients with lymph node metastases than in node-negative patients (30) (31) (32) . Our current result and one recent study confirm these reports (33) . Evaluation of c-erbB-2 staining as a risk factor for early recurrence in node-negative patients may not always be useful until further efforts have been made to identify the mechanism underlying the frequent occurrence of c-erbB-2 overexpression in the intraductal component. Our result showing that cathepsin D immunostaining correlated significantly with a favorable prognosis was paradoxical because patients with weakly positive results had a lower risk of early recurrence than those with strongly positive ones. The polyclonal antibody used in this study could react not only with 48-kDa protein but also with 34-kDa protein and their precursor 52-kDa protein which had two different glycosylated forms. The manner of immunohistologic staining was the sum of the reaction for those different forms which had different biological activities (34, 35) . Our result requires further investigations using different types of monoclonal antibodies against cathepsin D.
In summary, we showed that the most reliable risk factor for early recurrence of and/or death from breast cancer was high histologic grade, and that this was closely linked to p53 expression. Histologic grade is a practical indicator of risk for early recurrence and is supported by p53 immunoreaction.
